| For: | Borovcanin MM, Vesic K, Jovanovic M, Mijailovic NR. Galectin-3 possible involvement in antipsychotic-induced metabolic changes of schizophrenia: A minireview. World J Diabetes 2021; 12(10): 1731-1739 [PMID: 34754374 DOI: 10.4239/wjd.v12.i10.1731] |
|---|---|
| URL: | https://www.wjgnet.com/1948-9358/full/v12/i10/1731.htm |
| Number | Citing Articles |
| 1 |
Slavica Minic Janicijevic, Ivan P Jovanovic, Nevena M Gajovic, Milena M Jurisevic, Monojit Debnath, Nebojsa N Arsenijevic, Milica M Borovcanin. Galectin-3 mediated risk of inflammation in stable schizophrenia, with only possible secondary consequences for cognition. World Journal of Psychiatry 2022; 12(9): 1183-1193 doi: 10.5498/wjp.v12.i9.1183
|
| 2 |
Kah Kheng Goh, Cynthia Yi-An Chen, Tzu-Hua Wu, Chun-Hsin Chen, Mong-Liang Lu. Crosstalk between Schizophrenia and Metabolic Syndrome: The Role of Oxytocinergic Dysfunction. International Journal of Molecular Sciences 2022; 23(13) doi: 10.3390/ijms23137092
|
| 3 |
Nataša R. Mijailović, Katarina Vesic, Dragana Arsenijevic, Maja Milojević-Rakić, Milica M. Borovcanin. Galectin-3 Involvement in Cognitive Processes for New Therapeutic Considerations. Frontiers in Cellular Neuroscience 2022; 16 doi: 10.3389/fncel.2022.923811
|
| 4 |
Nataša R Mijailović, Ivan P Jovanovic, Ivica Petrovic, Katarina Vesic, Milica M Borovcanin. Diabetes mellitus type 2 as an underlying, comorbid or consequent state of mental disorders. World Journal of Diabetes 2023; 14(5): 481-493 doi: 10.4239/wjd.v14.i5.481
|
| 5 |
Milica M. Borovcanin, Bojan Stojanovic, Milica Dimitrijevic Stojanovic, Bojana S. Stojanovic, Aleksandar Lazovic, Marina Mitrovic. Cancer Treatment Modalities: An Interdisciplinary Approach. Interdisciplinary Cancer Research 2024; 24 doi: 10.1007/16833_2024_394
|
| 6 |
Büşra Sultan Sevindik, Özlem Olguner Eker, Akif Asdemir, Esra Kısacık, Ayşe Işık, Eser Kılıç, Ertuğrul Eşel. Serum Galectin‐1 and Galectin‐3 Levels and Their Relationship With Executive Functions and Memory in Patients With Major Depressive Disorder. Human Psychopharmacology: Clinical and Experimental 2026; 41(4) doi: 10.1002/hup.70052
|